AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2185006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes in Self-Control (DISC)
Number of subjects: 20
Study 2185006 — intervention group
Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 20
Study 379369 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-vented closed urinary drainage system
Number of subjects: 236
Study 379369 — intervention group
Group type: COMPARATOR
Intervention: Bag-vented drainage system
Number of subjects: 236
Study 31874652 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 396
Study 31874652 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 396
Study 31874652 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise + Glucose
Number of subjects: 396
Study 31874652 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 396
Study 27990776 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin with high carbohydrate (HC; 55% total energy carbohydrate) and high glycaemic index (HGI) meal
Number of subjects: 0
Study 27990776 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin with high carbohydrate (HC; 55% total energy carbohydrate) and low glycaemic index (LGI) meal
Number of subjects: 0
Study 27990776 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin with low carbohydrate (LC; 40% total energy carbohydrate) and HGI meal
Number of subjects: 0
Study 27990776 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (LC; 40% total energy carbohydrate) and HGI meal
Number of subjects: 0
Study 27990776 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (HC; 55% total energy carbohydrate) and HGI meal
Number of subjects: 0
Study 27990776 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (HC; 55% total energy carbohydrate) and low glycaemic index (LGI) meal
Number of subjects: 0
Study 26695796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency and intermediate frequency descent type treatment
Number of subjects: 1024
Study 26695796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat type treatment
Number of subjects: 1024
Study 26695796 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency descent type treatment
Number of subjects: 1024
Study 26695796 — intervention group
Group type: EXPERIMENTAL
Intervention: Total deafness type treatment
Number of subjects: 1024
Study 26695796 — intervention group
Group type: COMPARATOR
Intervention: Patients with vertigo/dizziness
Number of subjects: 1024
Study 26695796 — intervention group
Group type: COMPARATOR
Intervention: Patients without vertigo/dizziness
Number of subjects: 1024
Study 23392089 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent determinants identified through multivariate analysis
Number of subjects: 2776
Study 23392089 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP lowering intervention
Number of subjects: 2776
Study 23392089 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk factors
Number of subjects: 2776
Study 21869693 — intervention group
Group type: EXPERIMENTAL
Intervention: GW468816 (200 mg/d)
Number of subjects: 264
Study 21869693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 19968217 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (no flexion or car riding restrictions)
Number of subjects: 81
Study 19968217 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation group (with restrictions to avoid hip flexion >90 degrees and car riding for the first month)
Number of subjects: 81
Study 17828063 — intervention group
Group type: EXPERIMENTAL
Intervention: depo- and galvanophoresis with copper hydroxide-calcium
Number of subjects: 372
Study 15169706 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 6 months
Number of subjects: 63
Study 11465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation 2 g four times a day
Number of subjects: 21
Study 11465650 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 21
Study 9467039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (LV) administered weekly
Number of subjects: 0
Study 9467039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly high-dose LV
Number of subjects: 0
Study 9467039 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly high-dose LV with 5-fluorouracil (5-FU)
Number of subjects: 0
Study 9467039 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily x 5 LV with 5-FU
Number of subjects: 0
Study 9467039 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for toxicity (delaying treatment, dose reduction, octreotide)
Number of subjects: 0
Study 8649867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory stapedectomy (admitted on the day of surgery, released 1-2 hours after procedure)
Number of subjects: 20
Study 8649867 — intervention group
Group type: COMPARATOR
Intervention: In-patient stapedectomy (admitted the day before surgery, discharged 24 hours after procedure)
Number of subjects: 20
Study 1980266 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 1.1 mg
Number of subjects: 12
Study 1980266 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg
Number of subjects: 12
Study 1980266 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 12
Study 1980266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1980266 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg and 4.4 mg
Number of subjects: 12
Study 6259722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Estramustine phosphate
Number of subjects: 0
Study 6259722 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular polyestradiol phosphate plus oral ethinyl estradiol
Number of subjects: 0
Study 30383289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 mcg)
Number of subjects: 130
Study 30383289 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane block
Number of subjects: 130
Study 28658358 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliosit Orthodontic
Number of subjects: 53
Study 28658358 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT
Number of subjects: 53
Study 25630368 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutritional supplement without additional vitamins and minerals (LNS)
Number of subjects: 1815
Study 25630368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional vitamins and minerals (LNS-VM)
Number of subjects: 1815
Study 25630368 — intervention group
Group type: COMPARATOR
Intervention: LNS
Number of subjects: 1815
Study 25630368 — intervention group
Group type: EXPERIMENTAL
Intervention: LNS-VM
Number of subjects: 1815
Study 23577271 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (30 minutes of repeated maximum left thumb abduction) in the morning (8 AM)
Number of subjects: 22
Study 23577271 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training (30 minutes of repeated maximum left thumb abduction) in the evening (8 PM)
Number of subjects: 22
Study 19854074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 40
Study 19854074 — intervention group
Group type: COMPARATOR
Intervention: Control (no sitagliptin)
Number of subjects: 40
Study 18355326 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine without polysorbate-20 (R)
Number of subjects: 24
Study 18355326 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine with polysorbate-20 (T)
Number of subjects: 24
Study 18355326 — intervention group
Group type: COMPARATOR
Intervention: Both formulations of insulin glargine
Number of subjects: 24
Study 17240784 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 17
Study 17240784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 17240784 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 17
Study 14647265 — intervention group
Group type: COMPARATOR
Intervention: mini-ICE+filgrastim
Number of subjects: 38
Study 14647265 — intervention group
Group type: EXPERIMENTAL
Intervention: HiDAC+AMSA+filgrastim
Number of subjects: 38
Study 10963159 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade femoral nailing
Number of subjects: 68
Study 10963159 — intervention group
Group type: COMPARATOR
Intervention: Retrograde femoral nailing
Number of subjects: 68
Study 8607393 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg (n = 97)
Number of subjects: 200
Study 8607393 — intervention group
Group type: COMPARATOR
Intervention: Propafenone 450 mg (n = 103)
Number of subjects: 200
Study 8607393 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (maximum 300 mg/day)
Number of subjects: 200
Study 8607393 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (maximum 900 mg/day)
Number of subjects: 200
Study 1790601 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 460
Study 1790601 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens
Number of subjects: 460
Study 6791230 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 0
Study 31701267 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™
Number of subjects: 27
Study 31701267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynasplint Trismus System®
Number of subjects: 27
Study 30679290 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions facilitated by a trained health professional
Number of subjects: 0
Study 30679290 — intervention group
Group type: COMPARATOR
Intervention: Written information on advance care planning (current standard of care)
Number of subjects: 0
Study 30679290 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions
Number of subjects: 0
Study 28623638 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolock‐U 25,000 (urokinase 25,000, taurolidine, citrate 4%) once a week
Number of subjects: 0
Study 28623638 — intervention group
Group type: COMPARATOR
Intervention: Taurolock™‐HEP500 (heparin 500 IU/mL, taurolidine, citrate 4%) after each hemodialysis session
Number of subjects: 0
Study 28623638 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 25640807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive/triple antiplatelet therapy for one month
Number of subjects: 0
Study 25640807 — intervention group
Group type: COMPARATOR
Intervention: Guideline antiplatelets for one month
Number of subjects: 0
Study 24171182 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 90 mg and Stabilization Splint (SS)
Number of subjects: 94
Study 24171182 — intervention group
Group type: COMPARATOR
Intervention: Propranolol placebo and Stabilization Splint (SS)
Number of subjects: 94
Study 24171182 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 90 mg and Non-Occlusal Splint (NOS)
Number of subjects: 94
Study 24171182 — intervention group
Group type: COMPARATOR
Intervention: Propranolol placebo and Non-Occlusal Splint (NOS)
Number of subjects: 94
Study 21108337 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV-C infection among HIV-infected women
Number of subjects: 1719
Study 21108337 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV-C infection among HIV-uninfected women
Number of subjects: 1719
Study 21108337 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for GBV-C infection
Number of subjects: 1719
Study 21108337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of GBV-C RNA among women with GBV-C infection
Number of subjects: 1719
Study 19301691 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (an ARB)
Number of subjects: 0
Study 19301691 — intervention group
Group type: COMPARATOR
Intervention: Combination of telmisartan and ramipril
Number of subjects: 0
Study 19301691 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (an ACEI)
Number of subjects: 0
Study 17550044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (2 mg/kg 2 h before treatment and 1 mg/kg 20 min before treatment)
Number of subjects: 54
Study 17550044 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Number of subjects: 54
Study 17550044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Number of subjects: 54
Study 14762748 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I surgery (hyoid suspension, palatal surgery, and/or genioglossus advancement)
Number of subjects: 57
Study 14762748 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II surgery (maxillomandibular advancement)
Number of subjects: 57
Study 11321604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing exercise regimen (16-week duration)
Number of subjects: 16
Study 11321604 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 9495405 — intervention group
Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 27‐gauge, 119‐mm Whitacre
Number of subjects: 407
Study 9495405 — intervention group
Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 25‐gauge, 120‐mm Durasafe
Number of subjects: 407
Study 9495405 — intervention group
Group type: EXPERIMENTAL
Intervention: International Medical Devices' 26‐gauge, 124‐mm Gertie Marx
Number of subjects: 407
Study 9495405 — intervention group
Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 27‐gauge, 120‐mm Durasafe
Number of subjects: 407
Study 9495405 — intervention group
Group type: COMPARATOR
Intervention: All spinal needles
Number of subjects: 407
Study 8056717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 or 5.0 mg/day)
Number of subjects: 21
Study 8056717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8056717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 21
Study 3241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (15 mg/kg per min)
Number of subjects: 10
Study 3241254 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (30 ng/kg per min)
Number of subjects: 10
Study 3241254 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% NaCl, 5.4 ml/h)
Number of subjects: 10
Study 31847590 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction in elongated position
Number of subjects: 1050
Study 31847590 — intervention group
Group type: COMPARATOR
Intervention: Traditional carpal tunnel release
Number of subjects: 1050
Study 29804902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Number of subjects: 672
Study 29804902 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Number of subjects: 672
Study 29804902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 672
Study 29804902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 28372325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation intervention (CORDIAL)
Number of subjects: 16
Study 28372325 — intervention group
Group type: COMPARATOR
Intervention: Standardized Cognitive Training (active control)
Number of subjects: 16
Study 25560779 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective excavation
Number of subjects: 300
Study 25560779 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise excavation
Number of subjects: 300
Study 25560779 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 300
Study 23938374 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM)
Number of subjects: 0
Study 23938374 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy treated women
Number of subjects: 0
Study 23938374 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers
Number of subjects: 0
Study 23938374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment related toxicities (mucositis, diarrhea, decreased absolute neutrophil count, elevated glucose, cholesterol)
Number of subjects: 0
Study 21449676 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants other than paroxetine
Number of subjects: 131
Study 21449676 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 131
Study 21449676 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1360780 within the FKBP5 gene
Number of subjects: 131
Study 21449676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2677G>T in the ABCB1 gene
Number of subjects: 131
Study 21449676 — intervention group
Group type: EXPERIMENTAL
Intervention: rs130058 SNP within the 5‐HTR1B gene
Number of subjects: 131
Study 18155871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily, could be reduced to 50 mg twice daily)
Number of subjects: 1435
Study 18155871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study 18155871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1435
Study 16271819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hemispheres engaged (pseudoword condition)
Number of subjects: 0
Study 16271819 — intervention group
Group type: COMPARATOR
Intervention: Right hemisphere disengaged
Number of subjects: 0
Study 16271819 — intervention group
Group type: COMPARATOR
Intervention: No asymmetry in processing non-words
Number of subjects: 0
Study 14513241 — intervention group
Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for parents of children aged 0-7 years
Number of subjects: 0
Study 14513241 — intervention group
Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for parents and children aged 7-12 years
Number of subjects: 0
Study 14513241 — intervention group
Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for youths aged 13-18 years
Number of subjects: 0
Study 10867087 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specifics not provided)
Number of subjects: 1830
Study 10867087 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital revascularization (specifics not provided)
Number of subjects: 1830
Study 10867087 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (specifics not provided)
Number of subjects: 1830
Study 9354489 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic trunk rotatory muscle performance
Number of subjects: 65
Study 9354489 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (80 subjects, 38 females)
Number of subjects: 65
Study 8416053 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of Protirelin (synthetic TRH) intravenously
Number of subjects: 42
Study 8416053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2939126 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms folic acid
Number of subjects: 75
Study 2939126 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 75
Study 2939126 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma folate to 13 ng/ml or above
Number of subjects: 75
Study 30464411 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 administered via autoinjector (AI)
Number of subjects: 190
Study 30464411 — intervention group
Group type: COMPARATOR
Intervention: SB5 administered via prefilled syringe (PFS)
Number of subjects: 190
Study 30464411 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SB5 AI and SB5 PFS)
Number of subjects: 190
Study 27194048 — intervention group
Group type: COMPARATOR
Intervention: Single goal intervention
Number of subjects: 0
Study 27194048 — intervention group
Group type: COMPARATOR
Intervention: Multiple goal intervention
Number of subjects: 0
Study 27194048 — intervention group
Group type: COMPARATOR
Intervention: Control group (received information about community health resources)
Number of subjects: 0
Study 25436296 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate)
Number of subjects: 10
Study 25436296 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 10
Study 21953277 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-associated gene variant QPCTL rs2287019 C allele
Number of subjects: 6039
Study 21953277 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-associated gene variant LRP1B rs2890652 C allele
Number of subjects: 6039
Study 21953277 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR-associated gene variant LYPLAL1/SLC30A10 rs4846567 G allele
Number of subjects: 6039
Study 21953277 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR-associated gene variant VEGFA rs6905288 A allele
Number of subjects: 6039
Study 19495810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT) for 3 months in addition to self-management therapy
Number of subjects: 48
Study 19495810 — intervention group
Group type: COMPARATOR
Intervention: Self-management treatment
Number of subjects: 48
Study 19495810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT)
Number of subjects: 48
Study 17481662 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100 mouse units of Dysport)
Number of subjects: 50
Study 17481662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15754234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 112
Study 15754234 — intervention group
Group type: COMPARATOR
Intervention: Proximal Femur Nail (PFN)
Number of subjects: 112
Study 15754234 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA Classification
Number of subjects: 112
Study 12086383 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 F catheter
Number of subjects: 500
Study 12086383 — intervention group
Group type: COMPARATOR
Intervention: 6 F catheter
Number of subjects: 500